A total of 798 T2DM and ACS patients who underwent PCI were included in the present study. The mean age of these patients was 61 ± 10 years, and 72.7% of patients were men. The baseline clinical and laboratory characteristics of the study patients according to the AIP quartiles are listed in Table 1. Patients with higher AIP values tended to be younger, were predominantly male, had higher rates of current smoking and dyslipidaemia, and had lower rates of never smoking and diagnosis with unstable angina pectoris. Patients with higher AIP values were more likely to have higher levels of BMI, serum creatinine (SCr), uric acid, TC, LDL-C, triglycerides, and fasting plasma glucose (FPG), while have lower levels of pulse pressure (PP) and HDL-C. Use of medications, agiographic findings, and procedural results of the study patients according to the AIP quartiles are summarized in Table 2. Medications before admission, intraoperative anticoagulants, and periprocedural medications, except for β-blockers, did not differ among the different AIP groups. Medications at discharge, except for P2Y12 inhibitors, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (ACEIs/ARBs), and oral antidiabetic agents, were similar across the different AIP groups. More patients who had higher AIP values were treated with ACEIs/ARBs at discharge. The proportions of left main/three-vessel disease and two-vessel disease were different among the different AIP groups. Patients with higher AIP values tended to have a higher rate of chronic total occlusions, and a lower rate of heavy calcification lesions. The proportions of left circumflex artery and right coronary artery interventions were different among the different AIP groups. Patients with higher AIP values tended to have a lower rate of complete revascularization.
Table 1
Baseline clinical and laboratory characteristics of the study patients according to the AIP quartiles
Variable | Q1 n = 199 | Q2 n = 200 | Q3 n = 200 | Q4 n = 199 | P value |
Demographics | | | | | |
Age (years) | 63 ± 8 | 63 ± 10 | 61 ± 9 | 58 ± 12 | < 0.001 |
Male sex, n (%) | 125 (62.8) | 146 (73.0) | 153 (76.5) | 156 (78.4) | 0.002 |
Clinical values (on admission) | | | | | |
BMI (kg/m2) | 25.3 ± 3.1 | 25.4 ± 2.8 | 26.1 ± 3.1 | 27.0 ± 3.5 | < 0.001 |
SBP (mm Hg) | 133 ± 18 | 133 ± 17 | 130 ± 16 | 131 ± 16 | 0.116 |
DBP (mm Hg) | 75 ± 11 | 76 ± 10 | 75 ± 10 | 77 ± 11 | 0.203 |
PP (mm Hg) | 58 ± 16 | 58 ± 15 | 55 ± 15 | 54 ± 14 | 0.015 |
Risk factors | | | | | |
Smoking status | | | | | |
Current smoking, n (%) | 60 (30.2) | 77 (38.5) | 76 (38.0) | 111 (55.8) | < 0.001 |
Former smoking, n (%) | 33 (16.6) | 33 (16.5) | 38 (19.0) | 26 (13.1) | 0.455 |
Never smoking, n (%) | 106 (53.3) | 90 (45.0) | 86 (43.0) | 62 (31.2) | < 0.001 |
Chronically daily drinking, n (%) | 14 (7.0) | 18 (9.0) | 26 (13.0) | 21 (10.6) | 0.234 |
Family history of CHD, n (%) | 54 (27.1) | 60 (30.0) | 69 (34.5) | 56 (28.1) | 0.386 |
Hypertension, n (%) | 138 (69.3) | 137 (68.5) | 141 (70.5) | 130 (65.3) | 0.715 |
Dyslipidaemia, n (%) | 107 (53.8) | 174 (87.0) | 192 (96.0) | 195 (98.0) | < 0.001 |
Previous MI, n (%) | 36 (18.1) | 43 (21.5) | 40 (20.0) | 51 (25.6) | 0.301 |
Past PCI, n (%) | 47 (23.6) | 50 (25.0) | 50 (25.0) | 44 (22.1) | 0.891 |
Previous ischemic stroke or TIA, n (%) | 13 (6.5) | 13 (6.5) | 17 (8.5) | 8 (4.0) | 0.338 |
PAD, n (%) | 27 (13.6) | 29 (14.5) | 31 (15.5) | 35 (17.6) | 0.713 |
Cardiac failure, n (%) | 12 (6.0) | 13 (6.5) | 23 (11.5) | 19 (9.5) | 0.156 |
LVEF (%) | 64 (60–67) | 64 (60–68) | 65 (60–68) | 65 (59–68) | 0.963 |
Clinical presentation | | | | | |
UAP, n (%) | 171 (85.9) | 153 (76.5) | 150 (75.0) | 153 (76.9) | 0.033 |
NSTEMI, n (%) | 19 (9.5) | 28 (14.0) | 28 (14.5) | 25 (12.6) | 0.493 |
STEMI, n (%) | 9 (4.5) | 19 (9.5) | 22 (11.0) | 21 (10.6) | 0.088 |
Laboratory measurements (fasting state) | | | | | |
BUN (mmol/L) | 5.2 (4.3–6.3) | 5.4 (4.5–6.5) | 5.4 (4.6–6.2) | 5.5 (4.6–6.7) | 0.173 |
SCr (µmol/L) | 66.5 (59.3–73.6) | 69.2 (61.9–80.3) | 70.3 (62.2–81.3) | 71.5 (63.2–82.2) | < 0.001 |
UA (µmol/L) | 303.2 (271.7-347.2) | 321.3 (279.6–373.0) | 323.8 (282.5–386.0) | 368.5 (307.0-410.3) | < 0.001 |
TC (mmol/L) | 3.90 ± 0.96 | 4.06 ± 1.01 | 4.10 ± 0.99 | 4.47 ± 1.03 | < 0.001 |
LDL-C (mmol/L) | 2.23 ± 0.85 | 2.48 ± 0.84 | 2.48 ± 0.77 | 2.53 ± 0.76 | 0.001 |
HDL-C (mmol/L) | 1.23 ± 0.22 | 1.04 ± 0.17 | 0.95 ± 0.17 | 0.87 ± 0.14 | < 0.001 |
Triglycerides (mg/dl) | 0.88 (0.72-1.00) | 1.31 (1.18–1.48) | 1.71 (1.51–1.99) | 2.66 (2.25–3.38) | < 0.001 |
FPG (mg/dl) | 6.80 (6.12–8.23) | 7.17 (6.32–8.25) | 6.80 (5.91–7.88) | 7.65 (6.61–8.49) | < 0.001 |
Glycated haemoglobin (%) | 7.0 (6.6–8.1) | 7.3 (6.7–8.2) | 7.2 (6.6–8.1) | 7.3 (6.7-8.0) | 0.409 |
AIP | -0.1581 ± 0.1373 | 0.1029 ± 0.0482 | 0.2631 ± 0.0504 | 0.5272 ± 0.1773 | < 0.001 |
AIP indicates atherogenic index of plasma; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; CHD, coronary heart disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischemic attack; PAD, peripheral artery disease; LVEF, left ventricular ejection fraction; UAP, unstable angina pectoris; NSTEMI, non ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; BUN, blood urea nitrogen; SCr, serum creatinine; UA, uric acid; TC, total cholesterol; LDL-C, low-density lipoprotein-cholesterol; HDL-C, high-density lipoprotein-cholesterol; FPG, fasting plasma glucose. |
Table 2
Use of medications, agiographic findings, and procedural results of the study patients according to the AIP quartiles
Variable | Q1 n = 199 | Q2 n = 200 | Q3 n = 200 | Q4 n = 199 | P value |
Medications before admission | | | | | |
Aspirin, n (%) | 145 (72.9) | 149 (74.5) | 154 (77.0) | 146 (73.4) | 0.784 |
P2Y12 inhibitors, n (%) | 81 (40.7) | 81 (40.5) | 74 (37.0) | 80 (40.2) | 0.858 |
Statins, n (%) | 150 (75.4) | 143 (71.5) | 155 (77.5) | 142 (71.4) | 0.418 |
ACEIs/ARBs, n (%) | 55 (27.6) | 65 (32.5) | 72 (36.0) | 69 (34.7) | 0.300 |
β-blockers, n (%) | 70 (35.2) | 79 (39.5) | 93 (46.5) | 63 (31.7) | 0.016 |
Insulin, n (%) | 75 (37.7) | 73 (36.5) | 79 (39.5) | 63 (31.7) | 0.406 |
Oral antidiabetic agents, n (%) | 89 (44.7) | 98 (49.0) | 110 (55.0) | 90 (45.2) | 0.145 |
Intraoperative anticoagulants | | | | | |
Unfractionated heparin, n (%) | 168 (84.4) | 170 (85.0) | 154 (77.0) | 156 (78.4) | 0.086 |
LMWH, n (%) | 6 (3.0) | 7 (3.5) | 16 (8.0) | 10 (5.0) | 0.089 |
Bivalirudin, n (%) | 25 (12.6) | 23 (11.5) | 30 (15.0) | 33 (16.6) | 0.448 |
Perioperative medications | | | | | |
Aspirin, n (%) | 196 (98.5) | 198 (99.0) | 200 (100.0) | 196 (98.5) | 0.308 |
P2Y12 inhibitors, n (%) | 199 (100.0) | 200 (100.0) | 200 (100.0) | 199 (100.0) | - |
GP Ⅱb/Ⅲa receptor antagonist, n (%) | 29 (14.6) | 38 (19.0) | 45 (22.5) | 37 (18.6) | 0.246 |
Medications at discharge | | | | | |
Aspirin, n (%) | 196 (98.5) | 198 (99.0) | 200 (100.0) | 196 (98.5) | 0.308 |
Cilostazol, n (%) | 3 (1.5) | 2 (1.0) | 1 (0.5) | 4 (2.0) | 0.473 |
Clopidogrel, n (%) | 174 (87.4) | 183 (91.5) | 178 (89.0) | 190 (95.5) | 0.031 |
Ticagrelor, n (%) | 25 (12.6) | 17 (8.5) | 22 (11.0) | 9 (4.5) | 0.031 |
Statins, n (%) | 199 (100.0) | 200 (100.0) | 200 (100.0) | 199 (100.0) | - |
ACEIs/ARBs, n (%) | 81 (40.7) | 93 (46.5) | 105 (52.5) | 121 (60.8) | 0.001 |
β-blockers, n (%) | 138 (69.3) | 147 (73.5) | 155 (77.5) | 136 (68.3) | 0.155 |
Insulin, n (%) | 65 (32.7) | 76 (38.0) | 72 (36.0) | 57 (28.6) | 0.213 |
Oral antidiabetic agents, n (%) | 87 (43.7) | 120 (60.0) | 119 (59.5) | 105 (52.8) | 0.003 |
Angiographic findings | | | | | |
One-vessel disease, n (%) | 22 (11.1) | 15 (7.5) | 18 (9.0) | 25 (12.6) | 0.347 |
Two-vessel disease, n (%) | 68 (34.2) | 41 (20.5) | 42 (21.0) | 46 (23.1) | 0.004 |
LM/three-vessel disease, n (%) | 109 (54.8) | 144 (72.0) | 140 (70.0) | 128 (64.3) | 0.001 |
Proximal LAD stenosis, n (%) | 94(47.2) | 110 (55.0) | 97 (48.5) | 100 (50.3) | 0.428 |
Restenotic lesions, n (%) | 26 (13.1) | 26 (13.0) | 30 (15.0) | 29 (14.6) | 0.913 |
Trifurcation or bifurcation lesions, n (%) | 155 (77.9) | 162 (81.0) | 151 (75.5) | 148 (74.4) | 0.403 |
Chronic total occlusions, n (%) | 36 (18.1) | 46 (23.0) | 44 (22.0) | 57 (28.6) | 0.093 |
Thrombus lesions, n (%) | 7 (3.5) | 14 (7.0) | 12 (6.0) | 12 (6.0) | 0.478 |
Heavy calcification lesions, n (%) | 75 (37.7) | 69 (34.5) | 73 (36.5) | 48 (24.1) | 0.016 |
Lesions > 20 mm long, n (%) | 108 (54.3) | 112 (56.0) | 122 (61.0) | 117 (58.8) | 0.537 |
Procedural results | | | | | |
Target vessel territory | | | | | |
LM, n (%) | 13 (6.5) | 16 (8.0) | 9 (4.5) | 18 (9.0) | 0.313 |
LAD, n (%) | 104 (52.3) | 97 (48.5) | 100 (50.0) | 99 (49.7) | 0.899 |
LCX, n (%) | 64 (32.2) | 69 (34.5) | 42 (21.0) | 48 (24.1) | 0.007 |
RCA, n (%) | 69 (34.7) | 82 (41.0) | 100 (50.0) | 74 (37.2) | 0.011 |
DES use, n (%) | 174 (87.4) | 172 (86.0) | 161 (80.5) | 159 (79.9) | 0.097 |
BRS use, n (%) | 6 (3.0) | 7 (3.5) | 8 (4.0) | 11 (5.5) | 0.607 |
DCB use, n (%) | 12 (6.0) | 11 (5.5) | 19 (9.5) | 14 (7.0) | 0.409 |
Complete revascularization, n (%) | 136 (68.3) | 115 (57.5) | 110 (55.0) | 107 (53.8) | 0.012 |
AIP indicates atherogenic index of plasma; ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; LM, left-main artery; LAD, left anterior descending artery; LCX, left circumflex artery; RCA; right coronary artery; DES, drug-eluting stent; BRS, bioresorbable scaffold; DCB, drug-coated balloon. |
The median follow-up duration was 927 days (interquartile range, 774 to 1109 days), and during the follow-up period, 198 patients suffered from at least one adverse CV event, which was recorded in 33 (16.6%) patients from the Q1 group, 45 (22.5%) from the Q2 group, 54 (27.0%) from the Q3 group, and 66 (33.2%) from the Q4 group. In the 198 patients who had at least one adverse CV event, there were 20 deaths (18 deaths from CV causes and 2 deaths from non-CV causes), 17 cases of non-fatal ischemic stroke, 24 cases of non-fatal MI, and 180 cases of unplanned revascularization. Of these, 33 patients suffered two, 2 patients suffered three, and 2 patients suffered four adverse CV events. The baseline clinical and laboratory characteristics of the study patients stratified by the primary endpoint are shown in Table 3. Compared with those without events, patients with at least one event had higher levels of AIP. Patients with at least one event had higher rates of previous MI, past PCI, peripheral arterial disease (PAD), and cardiac failure, higher levels of PP, SCr, triglycerides, and FPG, but lower levels of diastolic blood pressure, HDL-C, and LVEF. Use of medications, agiographic findings, and procedural results of the study patients stratified by the primary endpoint are presented in Table 4. Medications before admission, except for ACEIs/ARBs, were not different between patients with and without events. Intraoperative anticoagulants and perioperative medications, except for aspirin, did not differ between patients with and without events. Medications at discharge, except for aspirin, cilostazol, and insulin, were similar between patients with and without events. Compared with those without events, patients with at least one event had higher rates of left main/three-vessel disease, restenotic lesions, and lesions > 20 mm long, but lower rates of one-vessel and two-vessel diseases. In terms of procedural results, more patients who suffered from at least one event used drug-coated balloon, and fewer patients who suffered from at least one event achieved complete revascularization.
Table 3
Baseline clinical and laboratory characteristics of the study patients stratified by the primary endpoint
Variable | No such events n = 600 | Primary endpoint n = 198 | P value |
Demographics | | | |
Age (years) | 61 ± 10 | 62 ± 10 | 0.435 |
Male sex, n (%) | 436 (72.7) | 144 (72.7) | 0.987 |
Clinical values (on admission) | | | |
BMI (kg/m2) | 26.1 ± 3.2 | 25.6 ± 3.1 | 0.087 |
SBP (mm Hg) | 131 ± 17 | 133 ± 16 | 0.399 |
DBP (mm Hg) | 77 ± 10 | 72 ± 10 | < 0.001 |
PP (mm Hg) | 55 ± 15 | 60 ± 15 | < 0.001 |
Risk factors | | | |
Smoking status | | | |
Current smoking, n (%) | 244 (40.7) | 80 (40.4) | 0.948 |
Former smoking, n (%) | 93 (15.5) | 37 (18.7) | 0.292 |
Never smoking, n (%) | 263 (43.8) | 81 (40.9) | 0.471 |
Chronically daily drinking, n (%) | 61 (10.2) | 18 (9.1) | 0.660 |
Family history of CHD, n (%) | 173 (28.8) | 66 (33.3) | 0.231 |
Hypertension, n (%) | 408 (68.0) | 138 (69.7) | 0.656 |
Dyslipidaemia, n (%) | 496 (82.7) | 172 (86.9) | 0.165 |
Previous MI, n (%) | 114 (19.0) | 56 (28.3) | 0.006 |
Past PCI, n (%) | 123 (20.5) | 68 (34.3) | < 0.001 |
Previous ischemic stroke or TIA, n (%) | 39 (6.5) | 12 (6.1) | 0.827 |
PAD, n (%) | 66 (11.0) | 56 (28.3) | < 0.001 |
Cardiac failure, n (%) | 39 (6.5) | 28 (14.1) | 0.001 |
LVEF (%) | 65 (60–68) | 63 (57–67) | 0.002 |
Clinical presentation UAP, n (%) | 467 (77.8) | 160 (80.8) | 0.376 |
NSTEMI, n (%) | 82 (13.7) | 18 (9.1) | 0.092 |
STEMI, n (%) | 51 (8.5) | 20 (10.1) | 0.493 |
Laboratory measurements (fasting state) | | | |
BUN (mmol/L) | 5.4 (4.5–6.3) | 5.6 (4.5–6.7) | 0.179 |
SCr (µmol/L) | 68.5 (60.9–78.5) | 70.7 (63.1–83.5) | 0.010 |
UA (µmol/L) | 333.2 ± 77.2 | 344.4 ± 78.9 | 0.079 |
TC (mmol/L) | 4.10 ± 1.03 | 4.24 ± 0.98 | 0.093 |
LDL-C (mmol/L) | 2.41 ± 0.83 | 2.47 ± 0.74 | 0.382 |
HDL-C (mmol/L) | 1.04 ± 0.22 | 0.96 ± 0.20 | < 0.001 |
Triglycerides (mmol/L) | 1.46 (1.04-2.00) | 1.67 (1.12–2.31) | 0.003 |
FPG (mmol/L) | 6.88 (6.12–8.01) | 7.89 (6.70–9.23) | < 0.001 |
Glycated haemoglobin (%) | 7.2 (6.6–8.1) | 7.4 (6.8–8.3) | 0.079 |
AIP | 0.1608 ± 0.2653 | 0.2535 ± 0.2919 | < 0.001 |
AIP | | | 0.001 |
Q1, n (%) | 166 (27.7) | 33 (16.7) | - |
Q2, n (%) | 155 (25.8) | 45 (22.7) | - |
Q3, n (%) | 146 (24.3) | 54 (27.3) | - |
Q4, n (%) | 133 (22.2) | 66 (33.3) | - |
Abbreviations as in Tables 1 and 2. |
Table 4
Use of medications, agiographic findings, and procedural results of the study patients stratified by the primary endpoint
Variable | No such events n = 600 | Primary endpoint n = 198 | P value |
Medications before admission | | | |
Aspirin, n (%) | 442 (73.7) | 152 (76.8) | 0.386 |
P2Y12 inhibitors, n (%) | 234 (39.0) | 82 (41.4) | 0.547 |
Statins, n (%) | 438 (73.0) | 152 (76.8) | 0.295 |
ACEIs/ARBs, n (%) | 183 (30.5) | 78 (39.4) | 0.021 |
β-blockers, n (%) | 233 (38.8) | 72 (36.4) | 0.535 |
Insulin, n (%) | 212 (35.3) | 78 (39.4) | 0.303 |
Oral antidiabetic agents, n (%) | 289 (48.2) | 98 (49.5) | 0.746 |
Intraoperative anticoagulants | | | |
Unfractionated heparin, n (%) | 486 (81.0) | 162 (81.8) | 0.798 |
LMWH, n (%) | 29 (4.8) | 10 (5.1) | 0.902 |
Bivalirudin, n (%) | 85 (14.2) | 26 (13.1) | 0.715 |
Perioperative medications | | | |
Aspirin, n (%) | 600 (100.0) | 190 (96.0) | < 0.001 |
P2Y12 inhibitors, n (%) | 600 (100.0) | 198 (100.0) | - |
GP Ⅱb/Ⅲa receptor antagonist, n (%) | 105 (17.5) | 44 (22.2) | 0.139 |
Medications at discharge | | | |
Aspirin, n (%) | 600 (100.0) | 190 (96.0) | < 0.001 |
Cilostazol, n (%) | 2 (0.3) | 8 (4.0) | < 0.001 |
Clopidogrel, n (%) | 545 (90.8) | 180 (90.9) | 0.974 |
Ticagrelor, n (%) | 55 (9.2) | 18 (9.1) | 0.974 |
Statins, n (%) | 600 (100.0) | 198 (100.0) | - |
ACEIs/ARBs, n (%) | 294 (49.0) | 106 (53.5) | 0.268 |
β-blockers, n (%) | 442 (73.7) | 134 (67.7) | 0.103 |
Insulin, n (%) | 190 (31.7) | 80 (40.4) | 0.024 |
Oral antidiabetic agents, n (%) | 324 (54.0) | 106 (53.5) | 0.909 |
Angiographic findings | | | |
One-vessel disease, n (%) | 72 (12.0) | 8 (4.0) | 0.001 |
Two-vessel disease, n (%) | 165 (27.5) | 32 (16.2) | 0.001 |
LM/three-vessel disease, n (%) | 363 (60.5) | 158 (79.8) | < 0.001 |
Proximal LAD stenosis, n (%) | 295 (49.2) | 106 (53.5) | 0.286 |
Restenotic lesions, n (%) | 62 (10.3) | 49 (24.7) | < 0.001 |
Trifurcation or bifurcation lesions, n (%) | 460 (76.7) | 156 (78.8) | 0.537 |
Chronic total occlusions, n (%) | 141 (23.5) | 42 (21.2) | 0.507 |
Thrombus lesions, n (%) | 38 (6.3) | 7 (3.5) | 0.139 |
Heavy calcification lesions, n (%) | 197 (32.8) | 68 (34.3) | 0.696 |
Lesions > 20 mm long, n (%) | 319 (53.2) | 140 (70.7) | < 0.001 |
Procedural results | | | |
Target vessel territory | | | |
LM, n (%) | 40 (6.7) | 16 (8.1) | 0.499 |
LAD, n (%) | 302 (50.3) | 98 (49.5) | 0.838 |
LCX, n (%) | 168 (28.6) | 52 (27.7) | 0.808 |
RCA, n (%) | 243 (40.5) | 82 (41.4) | 0.820 |
DES use, n (%) | 502 (83.7) | 164 (82.8) | 0.783 |
BRS use, n (%) | 27 (4.5) | 5 (2.5) | 0.219 |
DCB use, n (%) | 34 (5.7) | 22 (11.1) | 0.009 |
Complete revascularization, n (%) | 384 (64.0) | 84 (42.4) | < 0.001 |
Abbreviations as in Tables 1 and 2. |
Kaplan-Meier analyses revealed a significantly higher incidence of the primary endpoint (log-rank test, P = 0.001; Fig. 1a) and a marginally (but non-significantly) higher incidence of the key secondary endpoint (log-rank test, P = 0.114; Fig. 1b) in patients with higher AIP values. The difference of the incidence of the primary endpoint was mainly driven by the increase in unplanned repeat revascularization (log-rank test, P = 0.005; Fig. 1f) across the AIP quartiles. However, the incidence of all-cause death (log-rank test, P = 0.168; Fig. 1c), CV death (log-rank test, P = 0.459), non-fatal ischemic stroke (log-rank test, P = 0.167; Fig. 1d), and non-fatal MI (log-rank test, P = 0.636; Fig. 1e) at follow-up were similar among the AIP quartiles.
Table 5 shows univariate and multivariate Cox proportional hazards regression analyses for the primary endpoint at follow up, which includes AIP quartiles, age, BMI, PP, LVEF, SCr, LDL-C, FPG, glycosylated haemoglobin, sex, current smoking, hypertension, previous MI, past PCI, PAD, cardiac failure, clinical presentation, coronary artery disease (CAD) severity, restenotic lesions, lesions > 20 mm long, use of drug-coated balloon, complete revascularization, and use of insulin at discharge. Taking Q1 as the reference, multivariate analysis showed that the AIP for Q2, Q3, and Q4 increased the HRs for the incidence of the primary endpoint (Q2: HR 1.164, 95% CI 0.728–1.860; Q3: HR 1.640, 95% CI 1.032–2.606; Q4: HR 2.153, 95% CI 1.355–3.421). Moreover, AIP used as a continuous variable was independently predictive of the primary endpoint (HR, 2.581; 95% CI, 1.499–4.444; P = 0.001). Table 6 shows univariate and multivariate Cox proportional hazards regression analyses for the key secondary endpoint at follow up, which includes AIP quartiles, age, BMI, PP, LVEF, blood urea nitrogen, SCr, LDL-C, FPG, glycosylated haemoglobin, current smoking, hypertension, past PCI, PAD, cardiac failure, clinical presentation, CAD severity, lesions > 20 mm long, complete revascularization, and use of ACEIs/ARBs at discharge. Taking Q1 as the reference, multivariate analysis revealed that the AIP for Q2, Q3, and Q4 increased the HRs for the incidence of the key secondary endpoint (Q2: HR 1.063, 95% CI 0.397–2.849; Q3: HR 1.762, 95% CI 0.690–4.497; Q4: HR 2.613, 95% CI 1.024–6.666). Moreover, AIP used as a continuous variable was independently predictive of the key secondary endpoint (HR, 3.412; 95% CI, 1.086–10.723; P = 0.036).
Table 5
Relationship between the incidence of the primary endpoint and the AIP expressed as a categorical variable
Variables | Univariate analysis HR (95% CI) | P-value | Multivariate analysis HR (95% CI) | P-value |
AIP quartiles | | | | |
Q1 | Reference | | Reference | |
Q2 | 1.376 (0.878–2.156) | 0.164 | 1.164 (0.728–1.860) | 0.525 |
Q3 | 1.710 (1.109–2.636) | 0.015 | 1.640 (1.032–2.606) | 0.036 |
Q4 | 2.265 (1.491–3.440) | < 0.001 | 2.153 (1.355–3.421) | 0.001 |
Age | 1.005 (0.991–1.019) | 0.472 | 0.989 (0.972–1.007) | 0.219 |
BMI | 0.959 (0.916–1.005) | 0.078 | 0.931 (0.884–0.982) | 0.008 |
PP | 1.021 (1.012–1.029) | < 0.001 | 1.019 (1.008–1.029) | < 0.001 |
LVEF | 0.974 (0.959–0.990) | 0.002 | 0.987 (0.965–1.009) | 0.242 |
SCr | 1.013 (1.006–1.021) | 0.001 | 1.011 (1.003–1.020) | 0.010 |
LDL-C | 1.078 (0.916–1.269) | 0.366 | 1.021 (0.842–1.239) | 0.832 |
FPG | 1.201 (1.132–1.274) | < 0.001 | 1.192 (1.108–1.281) | < 0.001 |
Glycosylated haemoglobin | 1.067 (0.955–1.193) | 0.252 | 0.861 (0.739–1.003) | 0.055 |
Male sex | 0.966 (0.706–1.320) | 0.827 | 0.834 (0.549–1.266) | 0.394 |
Current smoking | 1.003 (0.755–1.332) | 0.983 | 1.256 (0.874–1.805) | 0.219 |
Hypertension | 1.068 (0.789–1.447) | 0.669 | 1.040 (0.732–1.478) | 0.825 |
Previous MI | 1.492 (1.095–2.033) | 0.011 | 0.812 (0.549–1.202) | 0.299 |
Past PCI | 1.723 (1.285–2.310) | < 0.001 | 1.157 (0.687–1.949) | 0.583 |
PAD | 2.511 (1.836–3.435) | < 0.001 | 1.601 (1.096–2.338) | 0.015 |
Cardiac failure | 1.951 (1.308–2.909) | 0.001 | 1.167 (0.661–2.062) | 0.594 |
Clinical presentation | | | | |
UAP | Reference | | Reference | |
NSTEMI | 0.677 (0.416–1.102) | 0.117 | 0.531 (0.310–0.909) | 0.021 |
STEMI | 1.098 (0.690–1.747) | 0.695 | 1.114 (0.649–1.913) | 0.695 |
CAD severity | | | | |
One-vessel disease | Reference | | Reference | |
Two-vessel disease | 1.756 (0.809–3.810) | 0.154 | 1.324 (0.589–2.975) | 0.497 |
LM/three-vessel disease | 3.541 (1.740–7.205) | < 0.001 | 1.876 (0.882–3.990) | 0.103 |
Restenotic lesions | 2.290 (1.658–3.163) | < 0.001 | 1.724 (0.947–3.138) | 0.075 |
Lesions > 20 mm long | 1.984 (1.461–2.695) | < 0.001 | 1.574 (1.132–2.189) | 0.007 |
DCB use | 1.913 (1.228–2.980) | 0.004 | 1.025 (0.589–1.784) | 0.931 |
Complete revascularization | 0.467 (0.352–0.619) | < 0.001 | 0.736 (0.538–1.008) | 0.056 |
Insulin at discharge | 1.396 (1.051–1.854) | 0.021 | 1.135 (0.818–1.574) | 0.448 |
Abbreviations as in Tables 1 and 2. |
Table 6
Relationship between the incidence of the key secondary endpoint and the AIP expressed as a categorical variable
Variables | Univariate analysis HR (95% CI) | P-value | Multivariate analysis HR (95% CI) | P-value |
AIP quartiles | | | | |
Q1 | Reference | | Reference | |
Q2 | 1.380 (0.555–3.432) | 0.488 | 1.063 (0.397–2.849) | 0.903 |
Q3 | 2.020 (0.865–4.720) | 0.104 | 1.762 (0.690–4.497) | 0.236 |
Q4 | 2.477 (1.085–5.659) | 0.031 | 2.613 (1.024–6.666) | 0.044 |
Age | 1.042 (1.013–1.072) | 0.004 | 1.017 (0.982–1.053) | 0.343 |
BMI | 0.915 (0.834–1.004) | 0.062 | 0.844 (0.751–0.948) | 0.004 |
PP | 1.030 (1.014–1.046) | < 0.001 | 1.012 (0.991–1.034) | 0.265 |
LVEF | 0.924 (0.902–0.946) | < 0.001 | 0.945 (0.906–0.984) | 0.007 |
BUN | 1.166 (1.018–1.335) | 0.026 | 0.868 (0.724–1.041) | 0.127 |
SCr | 1.025 (1.014–1.036) | < 0.001 | 1.016 (1.001–1.030) | 0.031 |
LDL-C | 1.064 (0.774–1.463) | 0.702 | 1.081 (0.714–1.636) | 0.713 |
FPG | 1.097 (0.967–1.243) | 0.150 | 1.017 (0.880–1.176) | 0.818 |
Glycated haemoglobin | 1.090 (0.882–1.347) | 0.425 | 1.220 (0.932–1.597) | 0.148 |
Current smoking | 1.014 (0.589–1.746) | 0.959 | 1.534 (0.824–2.855) | 0.177 |
Hypertension | 1.333 (0.725–2.450) | 0.354 | 1.266 (0.608–2.636) | 0.528 |
Past PCI | 1.904 (1.096–3.309) | 0.022 | 2.247 (1.170–4.313) | 0.015 |
PAD | 5.804 (3.402–9.902) | < 0.001 | 2.888 (1.545–5.399) | 0.001 |
Cardiac failure | 6.939 (3.993–12.061) | < 0.001 | 1.888 (0.767–4.648) | 0.167 |
Clinical presentation | | | | |
UAP | Reference | | Reference | |
NSTEMI | 1.333 (0.622–2.857) | 0.460 | 0.501 (0.199–1.258) | 0.141 |
STEMI | 1.920 (0.896–4.115) | 0.094 | 1.056 (0.427–2.610) | 0.906 |
CAD severity | | | | |
One-vessel disease | Reference | | Reference | |
Two-vessel disease | 0.201 (0.037–1.096) | 0.064 | 0.059 (0.009–0.402) | 0.004 |
LM/three-vessel disease | 1.910 (0.689–5.296) | 0.214 | 0.418 (0.121–1.444) | 0.168 |
Lesions > 20 mm long | 2.681 (1.411–5.029) | 0.003 | 1.828 (0.882–3.789) | 0.105 |
Complete revascularization | 0.403 (0.232-0.700) | 0.001 | 0.684 (0.348–1.343) | 0.270 |
ACEIs/ARBs at discharge | 2.933 (1.596–5.391) | 0.001 | 1.782 (0.883–3.599) | 0.107 |
Abbreviations as in Tables 1 and 2. |
Further evaluation of predictive value of AIP as a continuous variable for the primary endpoint was performed in different subgroups of the study population. Increased AIP value (per 1-unit) was consistently associated with the primary endpoint in different subgroups, including age < 60 versus ≥ 60 years, BMI < 28 versus ≥ 28 kg/m2, LDL-C ≤ 1.8 versus > 1.8 mmol/L, female versus male, with versus without hypertension, and non-ST versus ST segment elevation ACS (Fig. 2).
From the results of the multivariate Cox proportional hazards regression analyses, we calculated the Harrell’s C statistic for the predictive value of the primary endpoint. The Harrell’s C statistic of the variables, including BMI, PP, SCr, FPG, PAD, clinical presentation, and lesions > 20 mm long, was 0.697 versus 0.707 after the addition of AIP quartiles; the continuous NRI was 19.1% (7.9–35.6%; P < 0.001).